Aum Biosciences Announces Closing Of Usd $27Million In A "Series A" Round Of Funding To Advance Its Clinical Stage Pipeline Of Precision And Targeted Cancer Therapies
Aum Biosciences Announces Closing Of Usd $27Million In A "Series A" Round Of Funding To Advance Its Clinical Stage Pipeline Of Precision And Targeted Cancer Therapies
10/13/21, 2:30 AM
Round Type
series a
AUM Biosciences (AUM) today announced the successful completion of USD $27 million series A funding round. This will fuel AUM's vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to targeted drugs in oncology. The funding will also accelerate pipeline expansion and business growth. This round was led by private equity funds including Singapore-based Everlife and globally focused health sciences investment firm SPRIM Global investments (SGI).
Company Info
Additional Info
AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability, and scalability. To know more, visit www.aumbiosciences.com